Youping Zhang

3 weeks ago | biorxiv.org | Jie Zhang |Wenxuan Wu |Yun Wang |Youping Zhang

AbstractDespite the high efficacy of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) in treating acute promyelocytic leukemia (APL), approximately 10-20% of patients develop drug resistance due to mutations in PML-RARα and other factors. Here, it is demonstrated that inhibiting USP2 with ML364 or silencing USP2 reduces PML-RARα protein levels in both ATRA-sensitive and -resistant APL cells, an effect reversed by proteasome inhibition.